With the novel coronavirus stealing the show this year, innovation in the biotech space has been just… a little overshadowed by the race to develop a worldwide vaccine.
Considering the pandemic has taken more than 1.6 million lives across the globe, the “all-hands-on-deck” approach is certainly understandable.
But just because the vaccine race has taken center stage, doesn’t mean some investors need to have their eyes fixed on the Pfizers (PFE), BioNTechs (BNTX), Modernas (MRNA), and AstraZenecas (AZN) of the world.
Today, the clinical-stage biopharmaceutical company Arvinas (ARVN) is making some pretty big noise of its own. The drug company just released positive interim results from Phase 1 clinical trials for a new class of protein degrader drugs that show evidence of anti-tumor activity.
Ok, what exactly does this mean? Well, in a news release, Arvina said its ARV-110, protein degrader could be a best-in-class drug for estrogen receptor (ER) degradation and has performed better than the current leader, fulvestrant, in these categories.
While the drug is designed to treat men with metastatic castration resistant prostate cancer, the company says the drug is also doing well “in heavily pretreated patients with locally advanced or metastatic ER-positive / HER2 negative (ER+/HER2-) breast cancer.”
The news has already helped shares of Arvina stock soar more than 96%, sparking Ron Peck, Ph.D., CMO at Arvinas, to say:
“It is exciting to see that ARV-110 continues to be active and well tolerated in what we believe is the most heavily pretreated patient population that has ever been studied with an AR-directed therapy.”